

wherein antibodies in AIDS patient sera bind to Gag, Pol, or Env polypeptides of said HIV-1 variant virus,

wherein said antibodies bind to Gag, Pol, or Env polypeptides of the virus designated HIV-1_{MAL} deposited at the COLLECTION NATIONALE DES CULTURES DE MICRO-ORGANISMES (CNCM) under No. I-641, and

wherein the genetic structure of said HIV-1 variant is 5-LTR-gag-pol-vif-vpr-tat-rev-vpu-env-nef-LTR-3'.

40. (NEW) The HIV-1 variant virus of claim 39, wherein the nucleic acid of said HIV-1 variant virus can be detected by hybridization with a DNA probe comprising the genomic cDNA of HIV-1_{MAL}.

41. (NEW) The HIV-1 variant virus of claim 39, wherein the nucleic acid of said HIV-1 variant virus can be detected by hybridization with a DNA probe comprising a restriction enzyme fragment of the cDNA of HIV-1_{MAL}, and wherein the restriction enzyme is selected from the group consisting of *Ava*I, *Bam*HI, *Bgl*II, *Eco*RI, *Hinc*II, *Hind*III, *Kpn*I, *Nde*I, *Pst*I, *Sac*I, and *Xba*I.

REMARKS

Claims 23-41 are now pending in this application and claims 26-38 have been withdrawn from consideration. The Examiner has rejected claims 23-25.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com